Kiadis Crushed By EMA Rejection Of T-Cell Therapy
Launch Hopes For ATIR101 Pushed Back A Few Years
The Dutch company's dataset on its stem cell transplant adjunct ATIR101 is not enough to satisfy European regulators as the standard of care in post-transplant patients has changed since the original filing.
